Log in to search using one of your social media accounts:

 

Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older. (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news

Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
YARDLEY, Pa.--(BUSINESS WIRE)-- September 18, 2017 -- Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food& Drug Administration (FDA) approved the Company ’s New Drug Application (NDA) for Xhance... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 19, 2017 Category: Drugs & Pharmacology Source Type: news

Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2017 Category: Drugs & Pharmacology Source Type: news

Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus
Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus. The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive pulmonary disease. Get the full story at our sister site, Drug Delivery Business News. The post Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat Amgen Novartis sandoz Source Type: news

US FDA issues CRL to Hikma ’s generic version of GSK’s Advair Diskus
Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithKline's Advair Diskus (fluticasone propionate and s … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Teva launches AirDuo RespiClick, generic inhaled asthma therapies
Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid. AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered using Teva’s breath-activated RespiClick inhaler. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches AirDuo RespiClick, generic inhaled asthma therapies appeared first on Mas...
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Teva Pharmaceuticals Source Type: news

AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

ArmonAir RespiClick (Fluticasone Propionate Multidose Dry Powder Inhaler for Oral Inhalation) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ArmonAir RespiClick (fluticasone propionate inhalation powder) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo RespiClick (fluticasone propionate and salmeterol... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 30, 2017 Category: Drugs & Pharmacology Source Type: news

Flonase (Fluticasone Propionate Nasal Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Cutivate Lotion (Fluticasone Propionate Lotion) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Advair HFA (Fluticasone Propionate and Salmeterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Flovent Diskus (Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 10, 2016 Category: Drugs & Pharmacology Source Type: news

Cutivate Ointment (Fluticasone Propionate Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Flovent HFA (Fluticasone Propionate HFA) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 26, 2016 Category: Drugs & Pharmacology Source Type: news

Experience Journal: Asthma
Asthma is the most common chronic medical condition in the U.S., affecting nearly 10 percent of the population. The rate can be even higher in children; some Boston public schools report rates as high as 16 percent among students. Children growing up with asthma often face difficulty breathing, and they may feel isolated from their peers. While this condition can be disruptive to a child’s life, it can be well controlled with proper medical care. The Asthma Experience Journal, created by the Boston Children’s Hospital Department of Psychiatry and the Allergy and Asthma Program, includes sto...
Source: Thrive, Children's Hospital Boston - June 15, 2016 Category: Pediatrics Authors: Erin Horan Tags: Diseases & Conditions asthma Experience Journal Source Type: news

Advair Diskus (Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 23, 2016 Category: Drugs & Pharmacology Source Type: news

New Sandoz patient-centric inhaler now available to treat adults with COPD
Novel inhaler approved for adults with chronic obstructive pulmonary disease (COPD) (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 24, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Respiratory Patient care AirFluSal copd fluticasone propionate Forspiro inhaler Latest News salmeterol Seretide Accuhaler treatment adherence Source Type: news

fluticasone propionate (Cutivate)
Title: fluticasone propionate (Cutivate)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 9/15/2015 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - September 15, 2015 Category: Dermatology Source Type: news

Dissolvable tablets don’t work for people with severe allergies to grass pollen
It’s summertime and—if you’re in Eugene, Oregon—the livin’ is sneezy. Eugene is the nation’s top spot for allergies this week according to IMS Health, a health information company that provides allergy alerts for cities across the nation. Eugene residents can blame their runny noses and itchy eyes on the city’s abundant grasses, which are currently spewing high levels of pollen into the air. Eugene is just the tip of the allergy iceberg. If you live near a patch of green, you routinely inhale pollen. You’re in good company if your body reacts to it. More than 50 million Ameri...
Source: New Harvard Health Information - July 2, 2015 Category: Consumer Health News Authors: Beverly Merz Tags: Asthma and Allergies dissolvable tablets grass pollen allergies Source Type: news

Adding a LAMA to Salmeterol/Fluticasone Improves COPD Lung FunctionAdding a LAMA to Salmeterol/Fluticasone Improves COPD Lung Function
Adding a once-a-day long-acting muscarinic antagonist (LAMA) to salmeterol/fluticasone propionate (SAL/FP) improves outcomes in chronic obstructive pulmonary disease (COPD), according to a report from Australia and New Zealand. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 8, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

azelastine hydrochloride and fluticasone propionate (Dymista)
Title: azelastine hydrochloride and fluticasone propionate (Dymista)Category: MedicationsCreated: 4/20/2015 12:00:00 AMLast Editorial Review: 4/20/2015 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - April 20, 2015 Category: Allergy & Immunology Source Type: news

Is A Specific Corticosteroid Better for Treatment of Asthma Than Another?
Discussion Asthma is a chronic obstructive lung disease that affects many children and adults. There is a wide range of symptoms that people experience from occurring relatively rarely (ie intermittent asthma) to patients having daily symptoms of such intensity that they are life-threatening (ie chronic severe asthma). The goals of asthma management include patient education and medication management so patients have no or minimal symptoms, prevent exacerbations, have no activity restrictions, have normal pulmonary function tests, have no or minimal medication side effects and meet patient and family expectations. Well con...
Source: PediatricEducation.org - January 5, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023...
LifeScienceIndustryResearch.com adds “Flovent (Asthma) – Forecast and Market Analysis to 2023” to its store. Obtain sales forecast for Flovent from 2013-2023 in top eight countries (the US, France,...(PRWeb September 21, 2014)Read the full story at http://www.prweb.com/releases/flovent-asthma-market/forecast-analysis-to-2023/prweb12184430.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 21, 2014 Category: Pharmaceuticals Source Type: news

Mundipharma reports Phase III flutiform trial results in paediatric asthma
Mundipharma has reported results from a randomised, multicentre, Phase III trial of flutiform, a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler, to treat paediatric asthma. (Source: Drug Development Technology)
Source: Drug Development Technology - September 8, 2014 Category: Pharmaceuticals Source Type: news

Over-the-Counter Flonase Allergy Relief Approved
The FDA has approved over-the-counter Flonase Allergy Relief, or fluticasone propionate 50 mcg nasal spray, for treatment of hay fever or upper respiratory allergies, its maker GlaxoSmithKline announced. (Source: WebMD Health)
Source: WebMD Health - July 28, 2014 Category: Consumer Health News Source Type: news

FDA Clears OTC Flonase Nasal Spray for Allergy Relief FDA Clears OTC Flonase Nasal Spray for Allergy Relief
Fluticasone propionate 50 mcg nasal spray is the first and only OTC nasal spray for hay fever and upper respiratory allergies. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

Flonase Goes OTC
(MedPage Today) -- The FDA has approved over-the-counter sales for Flonase (fluticasone propionate), the nasal spray for allergies, its manufacturer said. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - July 25, 2014 Category: Allergy & Immunology Source Type: news

High-dose fluticasone effective against eosinophilic esophagitis, study shows
High doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis, a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils, research shows. However, some trial participants in the study did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with eosinophilic esophagitis are steroid-resistant. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 18, 2014 Category: Science Source Type: news

High-dose fluticasone effective against eosinophilic esophagitis
(NIH/National Institute of Allergy and Infectious Diseases) Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis, a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. However, some trial participants did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with eosinophilic esophagitis are steroid-resistant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2014 Category: Global & Universal Source Type: news

Steroid asthma inhalers restrict children’s growth
Conclusion This systematic review has found that inhaled corticosteroid drugs suppress growth in children with persistent asthma who take them regularly, during the first year of treatment. This was high quality, well-conducted research, and its conclusions are likely to be reliable.  While the results are likely to worry parents, uncontrolled asthma can restrict a child’s activities and lower their quality of life. In severe cases, it can lead to life-threatening asthma attacks. Even low-grade, persistent symptoms can lead to fatigue, underperformance or absence from school as well as psychological prob...
Source: NHS News Feed - July 17, 2014 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Mundipharma commences COPD trial
Mundipharma Research Limited (Mundipharma) has announced a major milestone in the development programme of flutiform® (fluticasone propionate/formoterol fumarate) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with the commencement of a key clinical trial. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 19, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Respiratory Source Type: news

FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included. "Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding "Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news

MHRA consults on reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate) from P to GSL
Source: MHRA Area: News Consultation ARM 83 seeks views on the reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate) from Pharmacy (P) to General Sales List (GSL). The Reclassification Summary and patient information leaflet as provided by the applicant company are available via the link below.   The closing date for receipt of comments is 1 Feb 2013. (Source: NeLM - News)
Source: NeLM - News - January 8, 2013 Category: Drugs & Pharmacology Source Type: news